Coming Soon – the MRC Framework for the Development, Design and Analysis of Stratified Medicine Research Dr David Crosby MRC Programme Manager for Methodology.

Slides:



Advertisements
Similar presentations
Mental health strategy of the Medical Research Council (UK) Opportunities for European engagement and a role of FEAM European Parliament 22 nd March 2011.
Advertisements

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.
Implementing NICE guidance
Application of the Benefits Analysis Tools for MRC population health studies Professor Dipak Kalra Centre for Health Informatics and Multiprofessional.
Introduction to the unit and mixed methods approaches to research Kerry Hood.
Exploring opportunities for health research collaborations between Australia and the UK Professor Nigel Mathers & Dr Susan Nancarrow Institute of General.
7 (a) Under what circumstances is stratified random sampling procedure is considered appropriate?How would you select such samples?Explain by means of.
Case study: The National Library for Health (NLH) Specialist Libraries An example of a Community of Practice.
EU rare diseases registry for Niemann-Pick Disease type A, B and C Tarekegn Hiwot Consultant in Inherited Metabolic Disorders University Hospital of Birmingham.
TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB.
Improving Quality of Trials through the MRC Network of Hubs for Trials Methodology Research Professor Lucinda (Cindy) Billingham Professor of Biostatistics.
Welcome to the NIHR Peter Knight, Deputy Director Research Contracting, Information Intelligence and Stakeholder Engagement NIHR Trainees Meeting Leeds.
Opportunities for Clinicians from MRC Dr Adam Babbs MRC Programme Manager University of Leeds Medical Academic Trainees’ Event 10 November 2014.
STATISTICS DEFINITION AND MEANING
The Cost-Effectiveness of Providing DAFNE to Subgroups of Predicted Responders J Kruger 1, A Brennan 1, P Thokala 1, S Heller 2 on behalf of the DAFNE.
CORE COMPETENCIES IN CLINICAL & TRANSLATIONAL RESEARCH: The Child Health Perspective I. Clinical & Translational Research Questions: Extract information.
Cancer Disparities Research Partnership Program Process & Outcome Evaluation Amanda Greene, PhD, MPH, RN Paul Young, MBA, MPH Natalie Stultz, MS NOVA Research.
Irish Health Research: Collaboration and Partnership HSE Regional Library & Information Health Research Seminar Dr. Steevens’ Hospital 11th February 2011.
R2HC Third Call for Proposals Launch
System of Environmental-Economic Accounting Advancing the System of Environmental-Economic Accounting Project (AEEA) Research Agenda Mark Eigenraam Senior.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.
Click to add title Household energy efficiency programme evaluation: does it tell us what we need to know? Dr Joanne Wade CXC
NISCHR Research Infrastructure for Wales Angela Martin Learning Disabilities, Autism and Neurodevelopmental disorders network (LDAN) Conference April 2013.
The cost-effectiveness of providing a DAFNE follow- up intervention to predicted non-responders J Kruger 1, A Brennan 1, P Thokala 1, S Heller 2 on behalf.
RESEARCH A systematic quest for undiscovered truth A way of thinking
Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.
ORIENTATION SESSION Strengthening Chronic Disease Prevention & Management.
Developing a ‘Bench to Bedside’ Commercial Collaboration Jo Chambers.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
CPTR Key Accomplishments: Research Resources Group October 3, 2012.
How Clinical Cancer Trials Work in the UK Henry Kitchener, University of Manchester ANZGOG March 2013.
Techniques for Data Linkage and Anonymisation – A Funders View Turing Gateway Meeting 23 rd October 2014 Dr Mark Pitman.
Steph Garfield-Birkbeck Assistant Director NIHR Evaluation Trials and Studies Coordinating Centre, University of Southampton.
EDRN Approaches to Biomarker Validation DMCC Statisticians Fred Hutchinson Cancer Research Center Margaret Pepe Ziding Feng, Mark Thornquist, Yingye Zheng,
Alzheimer’s disease Platforms for translational research.
Summary of ICIUM Chronic Care Track Prepared by: Ricardo Perez-Cuevas Veronika Wirtz David Beran.
Improving care for people with intellectual disabilities across the life span The ACI Intellectual Disability Network: Maxine Andersson Agency for Clinical.
Plymouth Health Community NICE Guidance Implementation Group Workshop Two: Debriding agents and specialist wound care clinics. Pressure ulcer risk assessment.
A translational routemap for public health research Peter Craig Programme Manager, MRC PHSRN Knowledge Transfer Scotland, Heriot Watt University, 23 April.
BCO Impact Assessment Component 3 Scoping Study David Souter.
Igniting our potential Research Governance Issues in Higher Education Brunswick Sub Group: 2 March 2006 Standardised Agreements.
Presentation/Phenotype
JOINT UN-ECE/EUROSTAT MEETING ON POPULATION AND HOUSING CENSUSES GENEVA, MAY 2009 DETERMINING USER NEEDS FOR THE 2011 UK CENSUS IAN WHITE, Office.
Horizon Scanning: future skills and competences of the health workforce in Europe MATT EDWARDS and JOHN FELLOWS WP6, EU JA on Health Workforce Planning.
Research How-To’s in a Community Setting Gregory W. Heath, DHSc, MPH Director of Research.
University of Kentucky Center for Clinical and Translational Science (CCTS) November 2015 Stephen W. Wyatt, DMD, MPH Senior Associate Director Center for.
Technology Needs Assessments under GEF Enabling Activities “Top Ups” UNFCCC/UNDP Expert Meeting on Methodologies for Technology Needs Assessments
PHE Local Intelligence Contribution David Meechan, Director for Knowledge & Intelligence (East Midlands), Public Health England.
NIHR Themed Call Prevention and treatment of obesity Writing a good application and the role of the RDS 19 th January 2016.
What evaluation attributes, stakeholder characteristics & contextual factors are important for evaluation influence? Sarah Appleton-Dyer Dr Janet Clinton,
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
What’s going on at the MRC John Savill Chief Executive Medical Research Council.
Realising MRC’s Vision in Health and Bioinformatics MRC Open Council Meeting July 2014 Janet Valentine Head of Population Health and Informatics.
Systemic change by streamlined innovation: personalised medicine Novembre 8, 2013.
What does the cancer intelligence landscape look like now? Dr Mick Peake Clinical Lead, National Cancer Intelligence Network.
Copyright © 2010, 2006, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 10 Evidence-Based Practice Sharon E. Lock.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
Patient and Public Involvement: Supporting a future of better research Isabelle Abbey-Vital, Research Involvement Officer.
Point of Care Testing for Personalised Medicine and Health
MRC’s Translational Research Funding
The DELTA2 Study: Summary of Methodology and Results
Clinical evaluation of UHC for cancer
Cough WORKING GROUP MEETING
Dr Joe McNamara Head of Population Health Sciences MRC
Experimental Medicine Challenge Grants Round 3
MIDD: Perspectives and Possibilities
Introduction to Basic Research Methods
NICE has many methods and processes
Presentation transcript:

Coming Soon – the MRC Framework for the Development, Design and Analysis of Stratified Medicine Research Dr David Crosby MRC Programme Manager for Methodology and Experimental Medicine UK Pharmacogenetics & Stratified Medicine Network Annual Open Meeting, 17 th March 2016

13 internationally competitive stratified medicine discovery engines Build on NIHR and DA clinical research funding Total investment c. £60m 3 charity co-funders (CRUK, ARUK, BHF) 32 academic and 51 commercial partners MRC Stratified Medicine Consortia COPDMAP RAMAP-I MASTERMIND GAUCHERITE STOP-HCV MATURA-I UKPBC STRATA PSORT MASTERPLANS RASP-UK AIM HY S-CORT Auto-Immune Respiratory Cancer Infections Mental Health Cardiovascular Diabetes Congenital RAMAP-II MATURA-II

Challenges Need for development of clinical descriptors in line with biomarker studies for both disease classification and drug response. If descriptors are weak, starting group definitions will be weak, making biomarker discovery more difficult Use of adaptive screens to identify and prioritize drivers of variability The development, in collaboration with clinical colleagues, of estimates of the diagnostic power required from a test used to direct therapy choice, if it is to impact clinical decision making. Such estimates can help in study design. How the different data types collected will be stored, integrated and shared both within the consortium and more widely Modelling capacity able to both identify statistically significant biomarkers and develop systems biomedicine models of disease mechanism

Why Methodology for Stratified Medicine? A cautionary note on data gathering and (over)interpretation: “And in his brain, which is as dry as the remainder biscuit after a voyage, he hath strange places crammed with observation, the which he vents in mangled forms.” 1 1 As You Like It, Act 2, Scene 7

Why Methodology for Stratified Medicine? Lack of clarity and consensus in the Stratified Medicine community on methodology and experimental design Lack of consideration of mechanistic plausibility Lack of reproducibility and clinical predictiveness Sporadic guidance in niche areas, but no existing unifying framework

The Process International expert steering group: Consortia, industry, diagnostics, statistics, informatics Workshop 40 invited participants Consortia, industry, diagnostics, statistics, informatics…. Epidemiology, behavioural research, regulators, systems biology Plenary presentations, thematically structured discussion

The Objective The Framework will cover methodological issues in: the discovery and verification of stratifying biomarkers the definition of strata by integration of marker information the diagnostic methodologies to facilitate this methods for deriving mechanistic insight from these markers/strata informing trials able to test new stratifying hypotheses. (not trial design or health economics) The purpose of the MRC Methodology for Stratified Medicine workshop was to inform the development of an MRC Framework for Development, Design and Analysis of Stratified Medicine Research (the Framework). The Framework publication is intended to provide guidance to investigators on current best practice in methodological design of stratified medicine research.

The Framework Mission

The Framework Structure 1.Framing the question/defining the population Team composition, defining phenotypically complex study populations, selecting and defining outcomes, mechanism 2.Designing Stratum Discovery Studies; selecting variables, defining response and powering Selecting variables to measure, effect and sample size, planning for verification 3.Assay Design; managing complexity and noise Sources of variability – pre-analytic/technical/operator, collecting meta data to look for drift/artefact 4.Defining Strata; data integration, linkage to existing knowledge, linkage to outcome Defining strata by multiple markers, dealing with high-dimensional data, clear and adaptable analysis plans 5.Stratum Verification Design to break association, dealing with inflated effect sizes from discovery work, data set selection 6.Progression Towards Clinical Utility Characteristics of stratifiers that “make it”, relevance of the research question to the clinic, requirements of trials and clinical assay development

Next steps First draft Consultation with workshop attendees Steering group redraft Online publication for full guidance Framework Journal publication for summary paper Dissemination and communications